Skip to content
Screener

Collegium Pharmaceutical, Inc. COLL Symproic and other — Product revenues, net

Other product segments

Belbuca
$57.67M+9.6%
Jornay PM
$46.06M+41.2%
Xtampza ER
$45.01M—
Nucynta ER
$15.72M-21.2%
Nucynta IR
$14.36M-45.8%
Azstarys
$12.91M—
Symproic
$3.02M-18.9%
Nucynta ER AG
$2.78M—
Nucynta IR AG
$2.36M—

Similar metrics at other companies

Vertex Pharmaceuticals logo
VRTXOther CF product revenues — Product revenues, net
$135.9M-12.5%
Vertex Pharmaceuticals logo
VRTXOther revenues — Product revenues, net
$0-100%
Vertex Pharmaceuticals logo
VRTXProduct revenues, net — Product revenues, net
$3.33B+13.2%
Vertex Pharmaceuticals logo
VRTXOther — Product revenues, net
$261M-6.8%
Vertex Pharmaceuticals logo
VRTXALYFTREK — Product revenues, net
$573.6M+266%
Vertex Pharmaceuticals logo
VRTXCASGEVY — Product revenues, net
$76.4M+151%

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$944.15M-1.3%
Enterprise value$798.74M-3.1%
P/E19.7×-6.7×
P/S1.2×-0.2×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Collegium Pharmaceutical, Inc.’s 10-K, filed February 26, 2026.

Filed
Feb 26, 2026, 7:34 AM EST
Fiscal year
FY2025
Accession
0001628280-26-011992
Line itemYears Ended December 31, 2025Years Ended December 31, 2024Years Ended December 31, 2023
Belbuca$221,653$211,269$182,095
Xtampza ER199,308191,330177,374
Jornay PM148,85737,239—
Nucynta IR115,312100,740108,150
Nucynta ER80,98575,76782,653
Symproic and other14,45215,10416,495
Total product revenues, net$780,567$631,449$566,767

Item 16. Form 10-K Summary

FAQ

What is Collegium Pharmaceutical, Inc.'s symproic and other — product revenues, net?
Collegium Pharmaceutical, Inc. (COLL) reported symproic and other — product revenues, net of $3.61M in Q4 2025.
How has Collegium Pharmaceutical, Inc.'s symproic and other — product revenues, net changed year-over-year?
Collegium Pharmaceutical, Inc.'s symproic and other — product revenues, net decreased by 4.3% year-over-year, from $3.78M to $3.61M.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s symproic and other — product revenues, net?
Over 2 years (2023 to 2025), Collegium Pharmaceutical, Inc.'s symproic and other — product revenues, net has grown at a -6.4% compound annual growth rate (CAGR), from $16.5M to $14.45M.
What does symproic and other — product revenues, net mean?
Represents the net sales generated from the Symproic product line and associated secondary offerings after accounting for returns, discounts, and rebates. This metric is a key indicator of market demand and commercial performance for this specific segment of the company's pharmaceutical portfolio.

Ask your AI about Collegium Pharmaceutical, Inc.'s symproic and other — product revenues, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude